Nasal Delivery of an Adenovirus-Based Vaccine Improves Immune Response in Mice
Author Information
Author(s): Croyle Maria A., Patel Ami, Tran Kaylie N., Gray Michael, Zhang Yi, Strong James E., Feldmann Heinz, Kobinger Gary P.
Primary Institution: The University of Texas at Austin
Hypothesis
Can nasal administration of an Ad5-based Ebola vaccine bypass pre-existing immunity and confer full protection upon challenge?
Conclusion
Nasal immunization with an Ad5-based vaccine can induce a protective immune response against Ebola virus in mice, even in the presence of pre-existing immunity.
Supporting Evidence
- Nasal immunization conferred 100% protection against lethal Ebola challenge in mice.
- Pre-existing immunity did not significantly compromise the immune response when vaccinated nasally.
- Intranasal vaccination induced significant T and B cell responses against Ebola glycoprotein.
Takeaway
This study shows that giving a vaccine through the nose can help mice fight off Ebola, even if they have already been exposed to a similar virus before.
Methodology
Mice were immunized with an adenovirus expressing Ebola glycoprotein via intramuscular, nasal, or oral routes, and their immune responses were assessed.
Potential Biases
Potential bias due to the use of a single animal model and specific viral strains.
Limitations
The study was conducted in mice, which may not fully replicate human responses.
Participant Demographics
B10.BR mice were used in the study.
Statistical Information
P-Value
0.07
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website